First Manhattan
GYRE icon

First Manhattan’s Gyre Therapeutics GYRE Stock Holding History

First Manhattan’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-34,171
Closed -$2.08M – 1399
2019
Q1 		$2.08M Hold
34,171
– – 0.01% 333
2018
Q4 		$2.02M Hold
34,171
– – 0.01% 341
2018
Q3 		$2.76M Buy
+34,171
New +$2.71M 0.01% 331

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return

First Manhattan's GYRE Position: Q2 2019 in Review

First Manhattan sold out of Gyre Therapeutics (GYRE) in Q2 2019, closing a stake of 34,171 shares — an estimated $2.08M sold.

First Manhattan first reported a position in GYRE in Q3 2018 and held it in 3 quarters. The position peaked at $2.76M in Q3 2018. 49 funds tracked by Wall St. Rank hold GYRE as of Q2 2019.

  • First Manhattan reported no remaining Gyre Therapeutics position as of Q2 2019 after selling out during the quarter.
  • First Manhattan sold 34,171 Gyre Therapeutics shares in Q2 2019, an estimated $2.08M.
  • First Manhattan first reported a position in Gyre Therapeutics in Q3 2018 and held it in 3 quarters.
  • First Manhattan's Gyre Therapeutics position peaked at $2.76M in Q3 2018.
  • 49 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2019.

Based on First Manhattan's 13F filing for Q2 2019, filed 16 Aug 2019.